Cancer Biomarkers Market Size

Cancer Biomarkers Market size was over USD 16.8 billion in 2024 and is anticipated to exceed USD 90.3 billion by the end of 2037, growing at over 13.7% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of cancer biomarkers is evaluated at USD 18.65 billion.

The growth of the market can be attributed to the growing patient base of various types of cancers comprising lung, prostate, breast, colorectal, ovarian cancer, and so on throughout the world. For instance, the number of new cancer cases in 2018 in the U.S. was 1,752,735 with the death of 599,589 people. Further, the rising consumer awareness regarding cancer biomarkers, coupled with the radically expanding use of cancer biomarkers for novel drug discovery, is estimated to hike the market growth during the coming years.

In addition to these, factors that are believed to fuel the market growth of cancer biomarkers include the worldwide rise in the geriatric population who are more vulnerable to fatal diseases such as cancer. Therefore, these individuals need the best possible care and prompt treatment for these conditions. According to the World Health Organization (WHO) estimations, the global population of individuals aged 60 and above is predicted to rise from 1 billion in 2020 to 1.4 billion by 2030. The world's population of individuals aged 60 and above is expected to double to 2.1 billion by 2050. Additionally, the growing proportion of research and development activities on cancer biomarkers, coupled with the increasing number of clinical research organizations across the world is expected to propel the growth of the cancer biomarkers market size during the forecast period. For instance, the number of clinical research organizations in 2022 across the world was nearly 3000 with a 0.3% rise from 2021.